IDH1 and cancer: IDH inhibitors, like ivosidenib and enasidenib, offer a targeted approach to reverse the inhibitory effect of 2-HG, an oncometabolite that accumulates in IDH-mutant cancers and inhibits TET enzymes, thereby restoring 5hmC levels and potentially improving outcomes, particularly in IDH-mutant AML [12, 53, 85]. Combination epigenetic therapies, such as using hypomethylating agents in combination with histone deacetylase inhibitors, are being investigated for their potential to reshape the cancer epigenome and improve treatment responses.